
The agency says CME has not shown imminent financial harm, while the exchange disputes how perpetual contracts should be regulated.
The U.S. Commodity Futures Trading Commission argued in a court filing that CME Group has not shown it is being harmed by the agency’s policy on perpetual futures. Without evidence of harm, the CFTC said, CME lacks legal standing to challenge the policy.
The agency said crypto futures volume at CME has risen since its policy shift. It also cited CME’s statements to investors that it had not heard of demand for perpetual contracts and did not consider them substitutes for its futures.
CME argues the contracts are swaps, not futures, because they have no expiration date. TD Cowen policy analyst Jaret Seiberg said CME may still have an advantage in its standing argument and its case for treating the contracts as swaps.
As of 17:06 UTC on Oct. 19, CME shares traded at $293.11, down 0.26% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.